Drug Trial Radar · NCT02608450
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
708
Actual
Start
Jan 21, 2016
Primary completion
Apr 11, 2018
Study completion Apr 11, 2018
Sponsor
- Lead sponsor
- Cassiopea SpAIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
CB-03-01 cream, 1%Drug
CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Vehicle creamDrug
Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)Time frame: Week 12
- Change From Baseline in Non-inflammatory Lesion CountsTime frame: Baseline and Week 12
- Change From Baseline in Inflammatory Lesion CountsTime frame: Baseline and Week 12
Locations
54 sites in 3 countries. Site status is shown where the registry gives one.
Gary M. Petrus, MD PA
Little Rock, Arkansas
Center For Dermatology Clinical Research, Inc.
Fremont, California
Vitiligo & Pigmentation Institute of Southern California
Los Angeles, California
San Diego Sports Medicine and Family Health Center
San Diego, California
Rady Childrens Hospital, Pediatric and Adolescent Dermatology
San Diego, California
Southern California Dermatology
Santa Ana, California
Clinical Science Institute
Santa Monica, California
Memorial Research Medical Clinic dba / Orange County Research Center
Tustin, California
Horizons Clinical Research Center, LLC
Denver, Colorado
Site 0190
Boca Raton, Florida
Study Protocol, Inc.
Boynton Beach, Florida
Site 0196
Miami, Florida
Site 0197
Miami, Florida
Site 0198
Miami, Florida
Site 0199
Miami, Florida
Site 0191
Miami, Florida
Site 0192
Miami, Florida
Site 0195
Miami, Florida
Tory Sullivan, M.D., P.A.
North Miami Beach, Florida
Meridien Research
St. Petersburg, Florida
MOORE Clinical Research, Inc.
Tampa, Florida
MedaPhase, Inc.
Newnan, Georgia
Site 0152
Carmel, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Henry Ford Health System
Detroit, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
The Center for Dermatology, Cosmetic & Laser Surgery
Mount Kisco, New York
DermResearch Center of New York, Inc.
Stony Brook, New York
Wake Research Associates
Raleigh, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Oregon Dermatology and Research Center
Portland, Oregon
The Pennsylvania State University and the Milton S. Hershey Medical Center
Hershey, Pennsylvania
Omega Medical Research
Warwick, Rhode Island
Greenville Dermatology, LLC
Greenville, South Carolina
International Clinical Research - Tennessee LLC
Murfreesboro, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
Westlake Dermatology Clinical Research Center
Austin, Texas
Bellaire Dermatology Associates
Bellaire, Texas
J&S Studies, Inc.
College Station, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.